BSW Wealth Partners Takes $324,000 Position in ChromaDex Co. (NASDAQ:CDXC)

BSW Wealth Partners bought a new position in ChromaDex Co. (NASDAQ:CDXC) during the third quarter, Holdings Channel reports. The fund bought 88,847 shares of the company’s stock, valued at approximately $324,000.

Several other hedge funds have also modified their holdings of CDXC. SG Americas Securities LLC acquired a new stake in ChromaDex during the 3rd quarter valued at $61,000. The Manufacturers Life Insurance Company purchased a new position in shares of ChromaDex during the second quarter valued at $31,000. Marshall Wace LLP acquired a new position in ChromaDex during the second quarter valued at $56,000. Merriman Wealth Management LLC acquired a new stake in ChromaDex during the 2nd quarter worth about $32,000. Finally, Renaissance Technologies LLC grew its stake in ChromaDex by 8.4% during the 2nd quarter. Renaissance Technologies LLC now owns 416,100 shares of the company’s stock valued at $1,136,000 after acquiring an additional 32,400 shares in the last quarter. 15.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of ChromaDex in a research report on Friday, August 9th.

Insider Transactions at ChromaDex

In related news, Director Kristin Patrick sold 23,000 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $3.57, for a total value of $82,110.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 9.64% of the stock is currently owned by company insiders.

ChromaDex Trading Up 67.9 %

Shares of NASDAQ:CDXC opened at $5.86 on Monday. The firm has a market cap of $444.95 million, a price-to-earnings ratio of 586.59 and a beta of 1.88. ChromaDex Co. has a 1 year low of $1.32 and a 1 year high of $5.98. The business has a fifty day simple moving average of $3.53 and a 200 day simple moving average of $3.23.

ChromaDex (NASDAQ:CDXC) last announced its quarterly earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. The business had revenue of $25.58 million during the quarter, compared to analysts’ expectations of $23.70 million. ChromaDex had a return on equity of 5.06% and a net margin of 1.62%. During the same quarter in the previous year, the business posted ($0.01) EPS. On average, sell-side analysts forecast that ChromaDex Co. will post 0.01 EPS for the current year.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.